The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session.Discover the Best Stocks and ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...